It's just an interesting question, why is that? Why, why are we-- what are the barriers to expanding more into other areas of healthcare? And, and maybe that's where the two tie up, right? Which is on the R&D side, there's this question of, well, what's preventing us from really utilizing this stuff in R&D? And also, what are the barriers to utilizing it on market as well? So I'm interested in both sides of that equation.

Yeah.

So definitely on the image analysis and diagnostics, there, there are new, better ways to diagnose disease earlier.

As you mentioned, imaging is a big part of it.

And in the R&D space, the in discovery, well, a-as I mentioned, technology and AI is being used in every step of the drug discovery and development process at this point, and for several years now.

In the discovery space, we're seeing new drugs emerging that we think are gonna be beneficial, are gonna be changing the trajectory of disease.

They still have to go through the clinical trials, which takes nine to twelve years.

Which pa-patient profile should we be recruiting in the first place?